FDA: ANDAs: Impurities in Drug Substances

Food and Drug Administration (FDA) published Guidance for Industry which provides revised recommendations on what chemistry, manufacturing, and controls (CMC) information to include regarding the reporting, identification, and qualification of impurities in drug substances produced by chemical synthesis when submitting original abbreviated new drug applications (ANDAs) or Drug master files (DMFs) including type II DMFs.